Dong O, Purser M, Herring WL, Mladsi DM, Gallagher M, Chawla A, Leiding JW, Andemariam B. Relationships among sickle cell disease complications and their implications for cost-effectiveness modeling for therapies with curative intent. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S115-6. doi: 10.1016/j.jval.2023.03.611
Ronquest N, Clinkscales M, Paret K. How are United States ICER'S evidence ratings determined?: A systematic review of ICER'S evidence ratings in evidence reports for new drugs in 2020 and 2021. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):299-300. doi: 10.1016/j.jval.2022.09.1479
Poulos C, Ng X, Mansfield C, Rosenberg S, Peay H, Lee J, Irony T, Ho M. Logical soundness in a discrete choice experiment study of benefit risk preferences. Presented at the ISPOR 2022 Conference; May 15, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).
Purser M, Gallagher M, Mladsi D, Weber JM, Andemariam B, Kaye JA, Chawla A. Evaluation of published models in sickle cell disease against key criteria for an economic model for a potentially curative one-time treatment. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2). doi: 10.1016/j.jval.2020.08.098
DiBenedetti D, Coles T, Ling CS, Sharma T, Pericleous L. Web-based study of patients and caregivers in the United States and Canada: perspectives on improvements in stability of factor viii products for hemophilia a. Poster presented at the 2013 ISPOR 18th Annual International Meeting; April 30, 2013. [abstract] Value Health. 2013 May; 16(3):A121.
DiBenedetti D, Coles T, Sharma T. Recruiting patients with a rare blood disorder and their caregivers through social media. Poster presented at the 2013 ISPOR 18th Annual International Meeting; April 23, 2013. [abstract] Value Health. 2013 May; 16(3):A51.
Roskell N, Mendelson E, Whalley D, Knight CJ. Using a condition-specific measure of patient-reported outcomes to derive utilities in myelofibrosis. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 7, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A224-5.
Roskell N, Wolowacz S, Christiansen AV, Plumb JM. Are double-blind, double-dummy studies suitable for resource utilisation analyses? An example from a new oral anticoagulant for the prevention of venous thromboembolism (VTE) following orthopaedic surgery. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):A167.
Wolowacz S, Roskell N, Plumb J, Clemens A, Robinson P, Dolan G, Brenkel I. Cost-effectiveness of dabigatran etexilate 150 mg for the prevention of venous thromboembolism in patients undergoing total hip or knee arthroplasty that have moderate impairment of renal function. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 1, 2009. [abstract] Value Health. 2009 May; 12(3):A151.
Wolowacz SE, Roskell NS, Plumb JM, Clemens A, Robinson P, Dolan G, Brenkel IJ. Cost-effectiveness of dabigatran etexilate 150 MG for the prevention of venous thromboembolism in patients aged over 75 years undergoing total hip or knee arthroplasty. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 14, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A151.
Mateus C, Wolowacz S, Pereira JA. Cost-effectiveness of dabigatran etexilate for the primary prevention of venous thromboembolism in total hip and knee replacement in Portugal. Poster presented at the 2009 ISPOR 14th Annual International Meeting; May 1, 2009. Orlando, FL. [abstract] Value Health. 2009 May; 12(3):A148.
Candrilli S, Balkrishnan R, O'Brien SH. The effect of injury severity on the incidence and resource utilization-related outcomes of deep vein thrombosis among pediatric trauma admissions in the United States. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 7, 2008. [abstract] Value Health. 2008 May; 11(3):A246-7.
Lee WC, Joshi AV, Brown TM, Pashos CL. Patient- and caregiver-reported preferences for characteristics of treatments for hemophilia patients with inhibitors. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. Toronto, Canada. [abstract] Value Health. 2008 May; 11(3):A164-5.
Pearson IV, Johnson KI. A cost minimization analysis of epoetin zeta for the treatment of anemia associated with chronic kidney disease. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. [abstract] Value Health. 2008 May; 11(3):A304.
Brown TM, Lee WC, Joshi AV, Pashos CL. Health-related quality of life of patients with hemophilia and inhibitors. Poster presented at the 2008 ISPOR 13th Annual International Meeting; May 2008. Toronto, Canada. [abstract] Value Health. 2008 May; 11(3):A154.
Lee WC, Joshi AV, Brown TM, Hadker N, Sumner M, Pashos CL. Physicians' preferences toward coagulation factor concentrates in the treatment of hemophilia patients with inhibitors: a discrete choice experiment. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research; October 2006. [abstract] Value Health. 2006 Nov; 9(6):A251.